Partnerships and Strategic Collaborations


Success originates through collaboration, by merging ORPHA Strategy's expertise and experience with that of our clients and selected partners, to create innovative solutions with the overriding goal of informing and supporting the timely market access of transformative medicines.

Ziphius Therapeutics is a global biopharmaceutical company dedicated to developing life-changing therapies for patients, families and caregivers affected by devastating diseases. 


Focused on preclinical drug development, the company acquires or invests in new, innovative technologies, hereby realizing further development to increase therapeutic potential. 


Today, Ziphius Therapeutics advances a portfolio of gene and cell therapy product candidates, with a focus on endocrinology, immunology, respiratory, and inflammatory therapeutic areas.


ORPHA Strategy's Principal, David Schwicker, will act as Strategic Advisor, supporting the Ziphius team with insights for business development, asset valuation, clinical and value evidence generation, patient- & caregiver-relevant outcomes and leveraging real-world evidence to accelerate the company's innovative programs.


Meet the Ziphius Team

BIOPHARMA GLOBAL Specialists Consulting for FDA & EMA Orphan Drug Development and Designations for Rare Diseases

A US-based corporation that operates as a not-for-profit, BioPharma Global offers FDA & EMA regulatory affairs and a complete suite of professional services to address the needs of emerging and growing biotech companies globally dedicated to rare disease research.

BioPharma Global specifically focusses on orphan drug designations and accelerated marketing authorisations, including FDA's expedited programs and EMA's PRIME.

Visit BIOPHARMA GLOBAL's website